(Total Views: 663)
Posted On: 02/04/2021 6:44:59 PM
Post# of 155004
Quote:
However, probably even if LL proves very effective at suppressing PDL1 expression in cancer cells, then LL and Opdivo will be used at the same time in all of the patients.
With sufficient downregulation of PD-L1 by leronlimab then Opdivo would not be used at all. If there is no receptor the ligand doesn't matter.
(3)
(0)
